PsO Patients With Cyclical Symptoms

Meet Divyam, a 26-year-old with moderate plaque PsO.¹

Patients with PsO such as Divyam whose symptoms have cyclical benefit from individualised treatment with Enbrel^®5-9

• Improvements observed over 54 weeks with both continuous and intermittent treatment across a wide range of physician- and patient-reported measures^5-7,*
   
  • Patients who paused and resumed treatment recaptured response and experienced sustained benefit^5-8

• Patients with PsO continue to benefit from long-term individualised Enbrel^®9,†
   
  • Improvements maintained up to 72 weeks with both continuous and interrupted treatment⁹
     
  • Both continuous and interrupted treatments were generally well-tolerated through 2.5 years⁹

From CRYSTEL, a randomised, open-label study that compared continuous and intermittent Enbrel^® dosing regimens in 720 patients with PsO.^5,*

PASI Improvement Over 54 Weeks⁵

P<0.01 for both groups versus baseline from Week 3 onwards. 
Adapted from Ortonne JP, et al. 2008.

Please consult the LPD for contraindications, warnings, precautions and other important safety information.

Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel^® (etanercept) could be considered.

*From CRYSTEL, a randomised, open-label, multicentre study of 720 patients with PsO treated (1:1) with continuous or intermittent Enbrel^®.⁵ From Weeks 3 to 54, both dose regimens significantly improved PGA and PASI scores versus baseline.^5,8 Significant improvements were also observed across a range of PROs, including DLQI, EQ-5D, HADS-D, HADS-A and SF-36 Vitality.⁶

Study design: Ortonne JP, et al. 2008.

In CRYSTEL, the continuous therapy group received Enbrel^® 25 mg BIW throughout the 54-week study. The intermittent therapy group received Enbrel^® 50 mg BIW for up to 12 weeks. Therapy was temporarily paused during that time when a target response (PGA ≤2) was achieved. When a patient subsequently relapsed (PGA ≥3), Enbrel^® (25 mg BIW for up to 24 weeks) was re-initiated until the target response was regained. Patients who failed to achieve the initial target response by Week 12, but whose PGA score improved by at least 1 unit, continued treatment with Enbrel^® 25 mg BIW for up to 24 weeks or until the target response was reached. In both treatment groups, patients who did not show improvement of at least 1 unit from baseline PGA by Week 12 were considered treatment failures, and were discontinued from the study.⁵
The trial’s primary endpoint was mean PGA over 54 weeks. Secondary endpoints included changes from baseline in mean PGA and PASI, and patient satisfaction with current PsO treatment.⁵
PROs evaluated included DLQI, EQ-5D, HADS and the SF-36 Vitality subscale.⁶

^†From a 72-week, long-term extension study. In total, 912 patients with PsO received 50 mg Enbrel^® QW for 12 weeks; thereafter, patients could maintain 50 mg QW (n=321) or escalate to 50 mg BIW (n=591) based on 1 of 3 predetermined criteria. Patients had experienced an interruption in Enbrel^® treatment between the last dose of the parent Phase 3 study and the first dose of this extension study, and comparisons were made between those with treatment gaps of ≤30 versus >30 days.⁹

BIW, twice a week; DLQI, Dermatology Life Quality Index; CRYSTEL, Clinical Randomized Year-long Study assessing the safety and efficacy of EnbreL in psoriasis; EQ-5D, EuroQoL-5D; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; PASI, Psoriasis Area and Severity Index; PGA, physician global assessment; PRO, patient-reported outcome; PsO, psoriasis; PUVA, psoralen plus ultraviolet A radiation; QW, once a week; SF-36, Short Form-36; SmPC, summary of product characteristics.

References: